Bulletin
Investor Alert

New York Markets Close in:

Vir Biotechnology Inc.

NAS: VIR

GO
/marketstate/country/us

Market open

 --Real time quotes

May 11, 2021, 1:44 p.m.

VIR
/zigman2/quotes/214486077/composite

$

39.33

Change

+0.58 +1.50%

Volume

Volume 346,122

Real time quotes

/zigman2/quotes/214486077/composite

Previous close

$ 38.75

$ 39.33

Change

+0.58 +1.50%

Day low

Day high

$35.81

$40.00

Open

52 week low

52 week high

$25.31

$141.01

Open

Company Description

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are desig...

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Valuation

Price to Sales Ratio

41.79

Price to Book Ratio

4.76

Enterprise Value to Sales

32.96

Total Debt to Enterprise Value

0.03

Efficiency

Revenue/Employee

233,541.00

Income Per Employee

-913,349.00

Total Asset Turnover

0.11

Liquidity

Current Ratio

7.80

Quick Ratio

7.80

Cash Ratio

7.52

Profitability

Operating Margin

-387.79

Pretax Margin

-391.02

Net Margin

-391.09

Return on Assets

-41.75

Return on Equity

-52.36

Return on Total Capital

-48.83

Return on Invested Capital

-49.41

Capital Structure

Total Debt to Total Equity

9.92

Total Debt to Total Capital

9.03

Total Debt to Total Assets

7.74

Long-Term Debt to Equity

9.38

Long-Term Debt to Total Capital

8.54

Officers and Executives

Name Age Officer Since Title
Dr. George A. Scangos 71 2017 President, Chief Executive Officer & Director
Mr. Howard Horn 42 2017 CFO, Secretary & Principal Accounting Officer
Dr. Michael E. Kamarck 68 2017 Chief Technology Officer
Dr. Phil Pang 44 2016 Chief Medical Officer
Dr. Herbert W. Virgin 63 2018 Chief Scientific Officer & Executive VP-Research

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
05/04/2021 Herbert W. Virgin
EVP, Research & CSO
1,375   Disposition at $46.03 per share. 63,291
05/04/2021 Herbert W. Virgin
EVP, Research & CSO
1,375   Derivative/Non-derivative trans. at $1.53 per share. 2,103
04/27/2021 Herbert W. Virgin
EVP, Research & CSO
7,900   Disposition at $49.5 per share. 391,050
04/27/2021 Herbert W. Virgin
EVP, Research & CSO
7,900   Derivative/Non-derivative trans. at $1.53 per share. 12,087
04/19/2021 Herbert W. Virgin
EVP, Research & CSO
2,340   Disposition at $48 per share. 112,320
04/19/2021 Herbert W. Virgin
EVP, Research & CSO
2,340   Derivative/Non-derivative trans. at $1.53 per share. 3,580
04/16/2021 Herbert W. Virgin
EVP, Research & CSO
3,500   Derivative/Non-derivative trans. at $1.53 per share. 5,355
04/13/2021 Herbert W. Virgin
EVP, Research & CSO
5,560   Disposition at $43.57 per share. 242,249
04/13/2021 Herbert W. Virgin
EVP, Research & CSO
5,560   Derivative/Non-derivative trans. at $1.53 per share. 8,506
04/09/2021 Herbert W. Virgin
EVP, Research & CSO
14,000   Derivative/Non-derivative trans. at $1.53 per share. 21,420
04/08/2021 ARCH Venture Partners LLC
5,989   0
04/08/2021 ARCH Venture Partners LLC
1,019   0
04/08/2021 ARCH Venture Partners LLC
3,161   0
04/08/2021 ARCH Venture Partners LLC
282,219   0
04/08/2021 ARCH Venture Partners LLC
217,781   0
04/08/2021 ARCH Venture Partners LLC
282,219   0
04/08/2021 ARCH Venture Partners LLC
217,781   0
04/07/2021 ARCH Venture Partners LLC
5,989   0
04/07/2021 ARCH Venture Partners LLC
1,019   0
04/07/2021 ARCH Venture Partners LLC
3,161   0
04/07/2021 ARCH Venture Partners LLC
282,219   0
04/07/2021 ARCH Venture Partners LLC
217,781   0
04/07/2021 ARCH Venture Partners LLC
282,219   0
04/07/2021 ARCH Venture Partners LLC
217,781   0
04/01/2021 ARCH Venture Partners LLC
1,016   0
04/01/2021 ARCH Venture Partners LLC
3,160   0
04/01/2021 Robert Taylor Nelsen
Director
5,987   0
04/01/2021 Jay Parrish
Chief Business Officer
2,315   Derivative/Non-derivative trans. at $1.58 per share. 3,657
04/01/2021 Jay Parrish
Chief Business Officer
4,629   Derivative/Non-derivative trans. at $1.48 per share. 6,850
04/01/2021 ARCH Venture Partners LLC
282,219   0
04/01/2021 ARCH Venture Partners LLC
217,781   0
04/01/2021 Jay Parrish
Chief Business Officer
6,944   Disposition at $51.4 per share. 356,921
03/30/2021 Robert Taylor Nelsen
Director
5,989   0
/news/latest/company/us/vir

MarketWatch News on VIR

  1. Lilly, Vir and Glaxo say combined monoclonal antibodies found 70% reduction in high viral load at day 7

    8:33 a.m. March 29, 2021

    - Ciara Linnane

  2. Eli Lilly, Vir and Glaxo announce positive data in Phase 2 trial of COVID antibody treatment

    8:33 a.m. March 29, 2021

    - Ciara Linnane

  3. GSK and Vir Submit Covid-19 Drug for FDA Authorization

    9:49 a.m. March 26, 2021

    - Josh Nathan-Kazis

  4. Glaxo and Vir say data from Phase 3 trial of antibody treatment shows 85% reduction in hospitalization or death

    8:33 a.m. March 26, 2021

    - Ciara Linnane

  5. GlaxoSmithKline and Vir Biotech have submitted EUA request to FDA for COVID antibody treatment

    8:32 a.m. March 26, 2021

    - Ciara Linnane

  6. You Can Buy a Tesla With Bitcoin Now

    8:28 a.m. March 24, 2021

  7. Regeneron Stock Climbs on Positive Covid-19 Antibody Data

    9:17 a.m. March 23, 2021

    - Josh Nathan-Kazis

  8. Regeneron Stock Climbs on Positive Covid-19 Antibody Data

    9:17 a.m. March 23, 2021

    - Josh Nathan-Kazis

  9. WHO declared a pandemic one year ago today

    6:59 a.m. March 12, 2021

    - Ciara Linnane

  10. Vir's Covid-19 Antibody Works Well, Sending Shares Flying

    8:38 a.m. March 11, 2021

    - Josh Nathan-Kazis

  11. Loading more headlines...
/news/nonmarketwatch/company/us/vir

Other News on VIR

  1. 7 Health-Focused ETFs To Buy Now For the Post-Covid Future

    2:10 p.m. April 29, 2021

    - InvestorPlace.com

  2. Eli Lilly (LLY) Q1 Earnings Miss, COVID-19 Drug Demand Low

    9:03 a.m. April 27, 2021

    - Zacks.com

  3. Vir Biotechnology: Gambling On Timing Of Headlines

    3:42 p.m. April 22, 2021

    - Seeking Alpha

  4. Vir Biotechnology: Not Nearly Enough

    6:10 p.m. April 21, 2021

    - Seeking Alpha

  5. Could Vir Biotechnology Be a Millionaire Maker Stock?

    6:00 a.m. April 17, 2021

    - Motley Fool

  6. EMA begins review of GSK/Vir early COVID-19 treatment VIR-7831

    10:53 a.m. April 15, 2021

    - Seeking Alpha

  7. Vir Biotechnology highlights new sars-cov-2 research

    9:13 a.m. April 8, 2021

    - Seeking Alpha

  8. Loading more headlines...

At a Glance

Vir Biotechnology, Inc.

499 Illinois Street

Suite 500

5th floor

San Francisco, California 94158

Phone

1 4159064324

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$76.37M

Net Income

$-298.67M

2020 Sales Growth

843.9%

Employees

327.00

/news/pressrelease/company/us/vir

Press Releases on VIR

  1. Vir Pushes for FDA Nod

    11:15 a.m. March 26, 2021

    - Baystreet.ca

  2. Effective Diagnostics Help to Tame the Spread of the Pandemic

    9:00 a.m. March 24, 2021

    - PR Newswire - PRF

  3. Loading more headlines...
Link to MarketWatch's Slice.